The FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9-2, with one abstention, Wednesday to recommend approval for The Medicines Co.'s (MDCO) cangrelor, but the panel's love for the drug wasn't much lovelier the second time around.